/
Infectious Disease
HIV-1 Infection
35
Pipeline Programs↗
37
Active Trials↗
19
Companies Involved↗
HIV-1 infection is a moderately active landscape with 35 programs across 19 companies. The most active players are Gilead, TaiMed Biologics Inc., Astellas. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 15
Phase 25
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
25 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 86% of 35 pipeline programs.
Analysis
Trial Status
118
clinical trials
Completed54 · 46%
Recruiting17 · 14%
Unknown status13 · 11%
Not yet recruiting11 · 9%
Terminated10 · 8%
Active, not recruiting9 · 8%
Other4 · 3%
Clinical Trials
Trial Activity
118 trials
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)